The spacious, expandable new home of the DPC Instrument Systems Division in Flanders, NJ. Necessitated by worldwide demand for IMMULITE® and IMMULITE® 2000 systems, the larger site will house Instrument and Software Development, Manufacturing, Field Services, Technical Services, and Customer Training Services for years.

DPC Cirrus, Inc. has a new name—DPC Instrument Systems Division—and spacious new headquarters, testimonies to the importance of the instrumentation and software arm of the DPC corporate family and to the worldwide acceptance of the IMMULITE^® and IMMULITE^® 2000 systems.

Art Babson, Ph.D., inventor of the IMMULITE, formed Cirrus Diagnostics Inc. in 1987. DPC acquired the company in 1992, thereby bringing together the New Jersey group’s instrument capabilities and the assay development experience in Los Angeles, for a synergy that resulted in a rapid adaptation of many DPC assays onto the IMMULITE platform. With the IMMULITE system, DPC was able to meet the growing market preference for fully automated immunoassay processing, all the while insisting on world-class service and support.

By the end of the third quarter of 2001, the numbers of IMMULITE and IMMULITE 2000 instruments placed around the world, since their 1993 and 1998 launches, totaled nearly 5200 and over 1600, respectively. It was the increasing demand for IMMULITE systems that necessitated relocation to a modern 90,000-square-foot facility in Flanders, New Jersey.

In step with evolving customer needs, the Company’s R&D departments in Los Angeles and New Jersey are developing the next generation IMMULITE system. The Flanders site will accommodate current and future Instrument and Software Development, Manufacturing, Field Services, Technical Services, and Customer Training Services for years, and can expand to a total of 150,000 square feet.